Threshold Pharmaceuticals, Inc (THLD): Opiniones

Era el unico valor que me quedaba en ING. Quería cerrar la cuenta.
Ahora toda mi artilleria está en http://www.activopro.es/ y http://www.activotrade.com/es/welcome.
Un saludo

me lo he perdido...sigo dentro pero esos 5,15 5,20 para saltar y si deja esa vela pincho moruno durante un año después de esa vela caídas.

veremos la hora que queda como la colocan.

me cago en mí ....

thld vendidas en 5.09

Bien jugado!.
Tienes pensado entrar en 4,3 o asi o ya la dejas por un tiempo?

La venta buena fue el otro día, se me escapo, y volver a entrar en 4.8. Ahora observar.

He encontrado esto por la web pero me falta el enlace para coraborarlo

$THLD Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC October 19 - 23, 2013

Asi es.

http://www.menafn.com/b54063c4-0c44-4a9d-98b2-7f9769fff45e/Threshold-Pharmaceuticals-Announces-New-Data-on-TH302-to-BePresented-at-AACRNCIEORTC?src=main

fase I y otra 1/2

nada, creo yo, que le haga tirar cohetes pero quizas un pequeño mete-saca si que pueda aprovecharse.
Estoy fuera del valor, vere mañana si se deja.

Por cierto, 4,71-4,72 umbral del bien y del mal diria ...

Threshold Pharmaceuticals Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC
Early Clinical Data on Combinations of TH-302 With Anti-Angiogenic Therapies in Solid Tumors; Preclinical Data on Combinations of TH-302 With Gemcitabine and Nab-Paclitaxel in Models of Pancreatic Cancer
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data on its investigational hypoxia-targeted drug, TH-302, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19 - 23, 2013, in Boston, MA. The presentations will characterize early data from two ongoing clinical trials evaluating combinations of TH-302 with anti-angiogenic agents in solid tumors as well as preclinical data on the tolerability and activity of TH-302, gemcitabine, and nab-paclitaxel combinations in models of pancreatic cancer.

New data from a Phase 1 clinical trial combining TH-302 and pazopanib (Investigator Sponsored Trial 4001) in patients with advanced solid tumors will be presented in a poster session on Tuesday, October 22 (Abstract #C61). Updated data from a Phase 1/2 clinical trial combining TH-302 and sunitinib (Study 410) in patients with renal cell carcinoma, gastrointestinal tumors, or pancreatic neuroendocrine tumors will be presented in a poster session on Monday, October 21 (Abstract #B77). Emerging preclinical research suggests that anti-angiogenic therapy may increase tumor hypoxia. These two clinical trials further characterize the potential of combining TH-302 with anti-angiogenic agents.

In addition, results from preclinical research evaluating combinations of TH-302, gemcitabine, and nab-paclitaxel in xenograft models of pancreatic cancer will be presented in a poster session on Tuesday, October 22 (Abstract #C287).

Abstracts are now available on the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Online Proceedings and Itinerary Planner Web page, which can be accessed at http://www.abstractsonline.com/plan/start.aspx?mkey=%7B18FA2242%2DFD0D%2D4689%2D82A0%2DE4D68AC8A74A%7D.